logo
logo

Rvac Medicines, A Cbc-Incubated Mrna Platform Company, Raises Us$140 Million To Expand R&D And Manufacturing Capacity

Apr 27, 2022•over 3 years ago

Amount Raised

$140 Million

Description

RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC Group ("CBC"), today announced the completion of its series B financing, bringing the company's total funds raised since its inception in June 2021 to US$140 million. RVAC aims to address unmet medical needs, particularly in emerging markets, through novel vaccines and therapeutics including a potential best-in-class COVID vaccine

Company Information

Company

Rvac

About

RVAC Medicines is an mRNA platform company headquartered in Singapore with R&D centers in Boston and Shanghai. Leveraging its mRNA technology and strategic partnerships, the company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. The company is led by an experienced management team, supported by a world-renowned scientific advisory board.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech